Temozolomide and thalidomide in the treatment of glioblastoma multiforme

M. Riva, F. Imbesi, E. Beghi, C. Galli, A. Citterio, P. Trapani, R. Sterzi, M. Collice

Research output: Contribution to journalArticlepeer-review


Objective: The aim of this study was to assess efficacy and toxicity of temozolomide given alone or in combination with thalidomide, an anti-angiogenetic drug, in patients with newly diagnosed glioblastoma multiforme (GBM). Patients and Methods: 46 patients with histologically proven GBM were eligible for inclusion. Twenty-three patients (15 males and 8 females) received temozolomide on a conventional schedule; 23 patients (12 males and 11 females) received temozolomide on the same schedule and thalidomide was dose-adjusted in each individual patient based on their tolerance. Results: The median survival time was 12 months for temozolomide and 13 months for temozolomide + thalidomide. Conclusion: The administration of temozolomide in association with thalidomide after radiotherapy (RT) does not offer an advantage over temozolomide alone in adults with newly diagnosed GBM. The two therapeutic strategies produce similar results for survival, but the latter regimen shows a moderate increase in toxicity.

Original languageEnglish
Pages (from-to)1067-1071
Number of pages5
JournalAnticancer Research
Issue number2
Publication statusPublished - Mar 2007


  • Chemotherapy
  • Glioblastoma
  • Temozolomide
  • Thalidomide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Temozolomide and thalidomide in the treatment of glioblastoma multiforme'. Together they form a unique fingerprint.

Cite this